This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jan 16, 2025
•
11 min read
Colossal Biosciences' $200M Series C furthers de-extinction ambitions, Eli Lilly's Omvoh lands FDA approval for Crohn's disease, Samsung Biologics considers building sixth plant to meet growing biologics demand, Pharma CEOs downplay IRA impacts on revenues as next round of CMS negotiations loom, FDA provides receipts on why they rejected Vanda Pharmaceuticals’ gastroparesis treatment hopeful tradipitant + 30 more stories
Jan 15, 2025
13 min read
Eli Lilly stock tumbles on slower-than-expected growth, Biohaven's IgAN hopeful BHV-1400 jumps from Ph1 direct to Ph3, Umoja Biopharma $100M Series C fuels CAR-T cell therapy clinical ambitions, REGENXBIO and Nippon Shinyaku partner on developing and commercializing two gene therapies for rare metabolic disorders, new FTC report accuses major pharmacy benefit managers of inflating drug prices and favoring affiliated pharmacies over independent ones + 37 more stories
Jan 14, 2025
14 min read
J&J drops $14.6B for Intra-Cellular Therapies, BMS exercises in-license option to ArsenalBio's solid tumor-targeting cell therapy, BlueRock Therapeutics jumps from Ph1 to Ph3 with their allogeneic cell therapy Parkinson's disease hopeful, Normunity $75M Series B to fuel solid tumor-targeting T cell engager ambitions, Nvidia signs a bunch AI-driven of healthcare partnership, Moderna's stock plunges 20% after cutting 2025 revenue forecast by $1B, former FDA Commissioner Scott Gottlieb is not a MAHA fan + 42 more stories
Jan 13, 2025
15 min read
$800M in company launches (5 in all!), Pfizer's subcutaneous PD-1 inhibitor succeeds in bladder cancer Ph3, Eli Lilly & a16z launch $500M biotech venture fund, Metsera files for IPO to fund obesity ambitions, Biogen makes $442M bid for partner Sage Therapeutics, AbbVie takes a $3.5B write-down after surprise Cerevel asset Ph2 failure + 40 more stories
Jan 10, 2025
Massive $410M Series A for just-launched obesity biotech Verdiva Bio, A2 Biotherapeutics $80M Series C for “logic-gated” cell therapies, GSK's rumored $1B IDRx takeover might be announced at JPM next week, Synaffix & Boehringer Ingelheim partner to develop next-gen ADCs, Intellia Therapeutics cuts 27% of workforce, Vanda Pharmaceuticals blasts FDA leadership (again) + 32 more stories
Jan 9, 2025
12 min read
Tenvie Therapeutics launches with $200M and neurological treatment assets acquired from Denali Therapeutics, Aspect Biosystems $115M Series B to fuel bioprinting tissue tech ambitions, Novo Nordisk & Valo Health expand $4.6B partnership to develop cardiometabolic drugs targeting obesity and diabetes, Galapagos splits in half (with 40% workforce reduction) + 32 more stories
Jan 8, 2025
Sana Biotechnology pushed the T1D boundary with sustained insulin delivery from implanted islet cells without immunosuppression, Avenzo Therapeutics in-licenses DualityBio's AVZO-1418/DB-1418 solid tumor-targeting bispecific, Aviceda Therapeutics $207.5M Series C fuels geographic atrophy ambitions into Ph3, Variant Bio and Novo Nordisk bet on novel drug discoveries through genetically diverse populations, Calico Life Sciences & Denali Therapeutics both face ALS clinical trial failures + 36 more stories
Jan 7, 2025
10 min read
FDA publishes new draft guidance regarding confirmatory trials in accelerated approvals, Amgen's lung cancer bispecific tarlatamab nabs UK conditional marketing nod, Merck & Co. buys Ireland-based Wuxi Biologics vaccine site, Aditum Bio closes $428M Fund III, Velia Therapeutics microprotein dreams go bust two years after a $55M Series A + 26 more stories
Jan 6, 2025
Regeneron acquires Oxular and gets hands on novel ocular drug delivery tech, BMS's Opdivo lands new approval for subcutaneous version, Roche in-licenses Innovent ADC in up to $1B deal, General Proximity launches with $16M to go after "undruggable" disease-linked proteins, Neumora stock collapses after navacaprant Ph3 failure in major depressive disorder + 31 more stories
Dec 20, 2024
Ottimo Pharma's CEO ready to "have some fun" with $140M Series A, BMS buys two preclinical Alzheimer's antibodies from BioArctic, KdT Ventures launches a currently unnamed rare disease start-up powered by an NGM Bio asset, US government nears shutdown as PBM reform thrown to the wayside + 31 more stories
Dec 19, 2024
Novartis & AbbVie score a 340B win in West Virginia, FDA approves Mesoblast's allogeneic mesenchymal stromal cell therapy (a US first), Novartis and BioAge Labs partner on age-related disease drug discovery, AstraZeneca likely taking a sales hit in China amid employee investigations + 36 more stories
Dec 18, 2024
Sandoz pays $275M to settle generic price-fixing litigation, Pfizer forecasts a more stable & upbeat 2025, Akamis Bio's $60M raise fuels oncolytic gene therapy ambitions, The Big Apple gets a CGT manufacturing hub, PBMs (unsurprisingly) fight back against PBM reform + 26 more stories
